Advancing together and moving forward: Combination gene and cellular immunotherapies

For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough).

Potentiating Cancer Immunotherapy Using an Oncolytic Virus

Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity

Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel

Three Decades of Clinical Gene Therapy: From Experimental Technologies to Viable Treatments

B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo

Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity

IL-21 Enhances Antitumor Responses without Stimulating Proliferation of Malignant T Cells of Patients with Sézary Syndrome

VSV Oncolytic Virotherapy in the B16 Model Depends Upon Intact MyD88 Signaling

Feasibility of Adenovirus-Mediated hNIS Gene Transfer and 131I Radioiodine Therapy as a Definitive Treatment for Localized Prostate Cancer

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Sodium Iodide Symporter SPECT Imaging of a Patient Treated With Oncolytic Adenovirus Ad5/3-Δ24-hNIS

Safer CARS